This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
1 J Plutzky (2000) Emerging concepts in metabolic abnormalities associated with coronary artery disease. Curr Opin Cardiol 15, 416–421.
2 JK Grover & SP Yadav (2004) Pharmacological actions and potential uses of Momordica charantia: a review. J Ethnopharmacol 93, 123–132.
3 MB Krawinkel & GB Keding (2006) Bitter gourd (Momordica charantia): a dietary approach to hyperglycemia. Nutr Rev 64, 331–337.
4 CY Chao & CJ Huang (2003) Bitter gourd (Momordica charantia) extract activates peroxisome proliferator-activated receptors and upregulates the expression of the acyl CoA oxidase gene in H4IIEC3 hepatoma cells. J Biomed Sci 10, 782–791.
5 B Desvergne & W Wahli (1999) Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20, 649–688.
6 JP Berger , TE Akiyama & PT Meinke (2005) PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci 26, 244–251.
10 P Arner (2005) Insulin resistance in type 2 diabetes – role of the adipokines. Curr Mol Med 5, 333–339.
11 KG Lambe & JD Tugwood (1996) A human peroxisome-proliferator-activated receptor-γ is activated by inducers of adipogenesis, including thiazolidinedione drugs. Eur J Biochem 239, 1–7.
17 GY Yeh , DM Eisenberg , TJ Kaptchuk & RS Phillips (2003) Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care 26, 1277–1294.
18 I Ahmed , E Adeghate , AK Sharma , DJ Pallot & J Singh (1998) Effects of Momordica charantia fruit juice on islet morphology in the pancreas of the streptozotocin-diabetic rat. Diabetes Res Clin Pract 40, 145–151.
19 T Miura , C Itoh , N Iwamoto , (2001) Hypoglycemic activity of the fruit of the Momordica charantia in type 2 diabetic mice. J Nutr Sci Vitaminol 47, 340–344.
22 TB Ng , CM Wong , WW Li & HW Yeung (1986) Insulin-like molecules in Momordica charantia seeds. J Ethnopharmacol 15, 107–117.
23 E Cummings , HS Hundal , H Wackerhage , M Hope , M Belle , E Adeghate & J Singh (2004) Momordica charantia fruit juice stimulates glucose and amino acid uptakes in L6 myotubes. Mol Cell Biochem 261, 99–104.
24 P De Vos , AM Lefebvre , SG Miller , M Guerre-Millo , K Wong , R Saladin , LG Hamann , B Staels , MR Briggs & J Auwerx (1996) Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor γ. J Clin Invest 98, 1004–1009.
26 A Okuno , H Tamemoto , K Tobe , (1998) Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101, 1354–1361.
27 I Bogacka , H Xie , GA Bray & SR Smith (2004) The effect of pioglitazone on peroxisome proliferator-activated receptor-γ target genes related to lipid storage in vivo. Diabetes Care 27, 1660–1667.
28 T Deng , S Shan , PP Li , ZF Shen , XP Lu , Z Cheng & ZQ Ning (2006) Peroxisome proliferator-activated receptor-γ transcriptionally up-regulates hormone-sensitive lipase via the involvement of specificity protein-1. Endocrinology 147, 875–884.
29 RS Ahima & JS Flier (2000) Adipose tissue as an endocrine organ. Trends Endocrinol Metab 11, 327–332.
30 GS Hotamisligil , P Peraldi , A Budavari , R Ellis , MF White & BM Spiegelman (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance. Science 271, 665–668.
31 ME Griffin , MJ Marcucci , GW Cline , K Bell , N Barucci , D Lee , LJ Goodyear , EW Kraegen , MF White & GI Shulman (1999) Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 48, 1270–1274.
32 JM Olefsky (1976) The effects of spontaneous obesity on insulin binding, glucose transport, and glucose oxidation of isolated rat adipocytes. J Clin Invest 57, 842–851.
33 E Hu , JB Kim , P Sarraf & BM Spiegelman (1996) Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARγ. Science 274, 2100–2103.
34 MS Brown , & JL Goldstein (1997) The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89, 331–340.
35 VW Yang , RJ Christy , JS Cook , TJ Kelly & MD Lane (1989) Mechanism of regulation of the 422(aP2) gene by cAMP during preadipocyte differentiation. Proc Natl Acad Sci U S A 86, 3629–3633.
36 Y Zhang , JJ Repa , K Gauthier & DJ Mangelsdorf (2001) Regulation of lipoprotein lipase by the oxysterol receptors, LXR LXRβ. J Biol Chem 276, 43018–43024.
39 JB Kim & BM Spiegelman (1996) ADD1/SREBP1 promotes adipocytes differentiation and gene expression linked to fatty acid metabolism. Genes Dev 10, 1096–1107.
40 DG Palmer , GA Rutter & JM Tavare (2002) Insulin-stimulated fatty acid synthase gene expression does not require increased sterol response element binding protein 1 transcription in primary adipocytes. Biochem Biophys Res Commun 291, 439–443.
41 F Bertile & T Raclot (2004) mRNA levels of SREBP-1c do not coincide with the changes in adipose lipogenic gene expression. Biochem Biophys Res Commun 325, 827–834.
42 M Sekiya , N Yahagi , T Matsuzaka , (2007) Sterol regulatory element-binding protein (SREBP)-1-independent regulation of lipogenic gene expression in adipocytes. J Lipid Res .
43 LK Juvet , SM Andresen , GU Schuster , (2003) On the role of liver X receptors in lipid accumulation in adipocytes. Mol Endocrinol 17, 172–182.
44 C Darimont , O Avanti , I Zbinden , P Leone-Vautravers , R Mansourian , V Giusti & K Mace (2006) Liver X receptor preferentially activates de novo lipogenesis in human preadipocytes. Biochimie 88, 309–318.
45 TM Stulnig , KR Steffensen , H Gao , M Reimers , K Dahlman-Wright , GU Schuster & J Gustafsson (2002) Novel roles of liver X receptors exposed by gene expression profiling in liver and adipose tissue. Mol Pharmacol 62, 1299–1305.